Patents by Inventor Brian Christopher Bales
Brian Christopher Bales has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11884686Abstract: The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known compounds.Type: GrantFiled: June 20, 2017Date of Patent: January 30, 2024Assignee: GE HEALTHCARE ASInventors: Andreas Richard Meijer, Mikkel Jacob Thaning, Brian Christopher Bales, Michael James Rishel
-
Patent number: 11754563Abstract: A device comprising a modified porous membrane is provided. The modified porous membrane comprises a polymer coating grafted to a porous membrane. The device is used for analyte detection from a biological sample using an immunoassay. The device comprises a sample application zone at one end of the device for applying a biological sample comprising a target analyte; and a detection zone present at another end of the device, downstream of the sample application zone for detecting the target analyte, wherein the detection zone comprises one or more first biomolecules immobilized on a modified porous membrane having a structure of Formula (I).Type: GrantFiled: November 20, 2014Date of Patent: September 12, 2023Assignee: GLOBAL LIFE SCIENCES SOLUTIONS OPERATIONS UK LTDInventors: Bing Li, Brian Christopher Bales, David Roger Moore, Jason Michael Nichols, Cathryn Ellen Olsen, William Christopher Alberts, Frank John Mondello
-
Patent number: 11714084Abstract: A rapid detection method of a target biomolecule comprising an antigenic moiety is provided. The method includes providing a source biological sample comprising the target biomolecule; contacting the source biological sample to an ion-exchange medium; eluting the captured-target biomolecule from the ion-exchange medium as an eluate, and loading the eluate to a rapid diagnostic testing device comprising an antibody. The eluate comprises a concentrated form of the biomolecule in a solution having a salt concentration greater than 150 mM. A concentration of the target biomolecule in the eluate is in a range from about 2× to 25× compared to a concentration of the biomolecule in the source biological sample. The target biomolecule binds to the antibody under the salt concentration of greater than 150 mM. A device for rapid detection of target biomolecule is also provided.Type: GrantFiled: November 5, 2020Date of Patent: August 1, 2023Assignee: General Electric CompanyInventors: Matthew Jeremiah Misner, Gregory Andrew Grossmann, Cathryn Ellen Olsen, John Richard Nelson, Brian Christopher Bales, David Roger Moore, Paul Michael Smigelski, Jr.
-
Patent number: 11110186Abstract: The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known compounds.Type: GrantFiled: December 20, 2018Date of Patent: September 7, 2021Assignee: GENERAL ELECTRIC COMPANYInventors: Brian Christopher Bales, Michael James Rishel
-
Publication number: 20210055297Abstract: A rapid detection method of a target biomolecule comprising an antigenic moiety is provided. The method includes providing a source biological sample comprising the target biomolecule; contacting the source biological sample to an ion-exchange medium; eluting the captured-target biomolecule from the ion-exchange medium as an eluate, and loading the eluate to a rapid diagnostic testing device comprising an antibody. The eluate comprises a concentrated form of the biomolecule in a solution having a salt concentration greater than 150 mM. A concentration of the target biomolecule in the eluate is in a range from about 2× to 25× compared to a concentration of the biomolecule in the source biological sample. The target biomolecule binds to the antibody under the salt concentration of greater than 150 mM. A device for rapid detection of target biomolecule is also provided.Type: ApplicationFiled: November 5, 2020Publication date: February 25, 2021Inventors: Matthew Jeremiah Misner, Gregory Andrew Grossmann, Cathryn Ellen Olsen, John Richard Nelson, Brian Christopher Bales, David Roger Moore, Paul Michael Smigelski
-
Patent number: 10837962Abstract: A rapid detection method of a target biomolecule comprising an antigenic moiety is provided. The method includes providing a source biological sample comprising the target biomolecule; contacting the source biological sample to an ion-exchange medium; eluting the captured-target biomolecule from the ion-exchange medium as an eluate, and loading the eluate to a rapid diagnostic testing device comprising an antibody. The eluate comprises a concentrated form of the biomolecule in a solution having a salt concentration greater than 150 mM. A concentration of the target biomolecule in the eluate is in a range from about 2× to 25× compared to a concentration of the biomolecule in the source biological sample. The target biomolecule binds to the antibody under the salt concentration of greater than 150 mM. A device for rapid detection of target biomolecule is also provided.Type: GrantFiled: December 20, 2017Date of Patent: November 17, 2020Assignee: GENERAL ELECTRIC COMPANYInventors: Matthew Jeremiah Misner, Gregory Andrew Grossmann, Cathryn Ellen Olsen, John Richard Nelson, Brian Christopher Bales, David Roger Moore, Paul Michael Smigelski, Jr.
-
Publication number: 20200338217Abstract: The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known compounds.Type: ApplicationFiled: December 20, 2018Publication date: October 29, 2020Inventors: Brian Christopher BALES, Michael James RISHEL
-
Patent number: 10730897Abstract: The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known compounds.Type: GrantFiled: December 21, 2017Date of Patent: August 4, 2020Assignee: GE HEALTHCARE ASInventors: Mikkel Jacob Thaning, Andreas Richard Meijer, Brian Christopher Bales, Michael James Rishel
-
Publication number: 20200062791Abstract: The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known compounds.Type: ApplicationFiled: December 21, 2017Publication date: February 27, 2020Inventors: Mikkel Jacob THANING, Andreas Richard MEIJER, Brian Christopher BALES, Michael James RISHEL
-
Publication number: 20190233450Abstract: The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known compounds.Type: ApplicationFiled: June 20, 2017Publication date: August 1, 2019Inventors: Andreas Richard MEIJER, Mikkel Jacob THANING, Brian Christopher BALES, Michael James RISHEL
-
Publication number: 20190187142Abstract: A rapid detection method of a target biomolecule comprising an antigenic moiety is provided. The method includes providing a source biological sample comprising the target biomolecule; contacting the source biological sample to an ion-exchange medium; eluting the captured-target biomolecule from the ion-exchange medium as an eluate, and loading the eluate to a rapid diagnostic testing device comprising an antibody. The eluate comprises a concentrated form of the biomolecule in a solution having a salt concentration greater than 150 mM. A concentration of the target biomolecule in the eluate is in a range from about 2× to 25× compared to a concentration of the biomolecule in the source biological sample. The target biomolecule binds to the antibody under the salt concentration of greater than 150 mM. A device for rapid detection of target biomolecule is also provided.Type: ApplicationFiled: December 20, 2017Publication date: June 20, 2019Inventors: Matthew Jeremiah Misner, Gregory Andrew Grossmann, Cathryn Ellen Olsen, John Richard Nelson, Brian Christopher Bales, David Roger Moore, Paul Michael Smigelski, JR.
-
Patent number: 9827335Abstract: The present application discloses treating water insoluble nanoparticles, particularly nanoparticles of metals and metal compounds which find utility in diagnostic imaging such as MR and X-ray imaging, with an alpha-hydroxyphosphonic acid conjugate with a hydrophilic moiety to render the nanoparticles sufficiently hydrophilic to find utility in diagnostic imaging. Among the modified hydrophilic nanoparticles disclosed are those in which the hydrophilic moieties of the modifying conjugate are ethylene oxide based polymers and copolymers and zwitterions and the nanoparticles are composed of transition metal oxides such as superparamagnetic iron oxide and tantalum oxide. Disclosed are nanoparticles which are sufficiently hydrophilic to form stable aqueous colloidal suspensions. Also disclosed is diagnostic imaging such as MR and X-ray using the modified hydrophilic nanoparticles as contrast agents.Type: GrantFiled: October 21, 2015Date of Patent: November 28, 2017Assignee: General Electric CompanyInventors: Brian Christopher Bales, Bruce Allan Hay, Binil Itty Ipe Kandapallil
-
Patent number: 9534214Abstract: A solid substrate for biological sample storage under dry-state and elution of biomolecules is provided. The dry, solid substrate is coated with saccharides, such as monosaccharides, oligosaccharides, polysaccharides or combinations thereof, and the substrate is comprised of one or more protein denaturing agents impregnated therein under a substantially dry state. A method for elution of biomolecules from biological samples is also provided. The compositions disclosed herein provide for enhanced elution and recovery of biomolecules, such as nucleic acids, from the sample. The sample is disposed on a substrate, dried to a substantially dry state; eluted from the biological sample dried on the substrate by rehydrating the substrate in an elution buffer.Type: GrantFiled: October 31, 2013Date of Patent: January 3, 2017Assignee: General Electric CompanyInventors: Bing Li, Gregory Andrew Grossmann, Erik Leeming Kvam, Brian Christopher Bales, Jason Louis Davis
-
Patent number: 9474810Abstract: The present application discloses nanoparticles, particularly nanoparticles of superparamagnetic iron oxide, which find utility in iron therapy and diagnostic imaging such as magnetic resonance (MR). The disclosed nanoparticles have been treated with an ?-hydroxyphosphonic acid conjugate containing polyethylene glycol as a hydrophilic moiety to render the nanoparticles sufficiently hydrophilic to find utility in diagnostic imaging. Among the modified hydrophilic nanoparticles disclosed are those in which the hydrophilic moieties of the modifying conjugate are polyethylene oxide-based polymers and have a molecular weight greater than 5,000 dalton and less than or equal to about 30,000 daltons. Surprisingly, these nanoparticles have a more rapid and complete processing in liver of retained nanoparticles when compared to similar nanoparticles in which the PEG-based hydrophilic moiety has a molecular weight less than 5,000.Type: GrantFiled: March 2, 2012Date of Patent: October 25, 2016Assignee: General Electric CompanyInventors: Bruce Allan Hay, Daniel Eugene Meyer, Brian Christopher Bales, Michael Todd Luttrell
-
Patent number: 9399075Abstract: Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprising a nanoparticulate transition metal oxide covalently functionalized with a silane-functionalized non-targeting zwitterionic moiety.Type: GrantFiled: April 29, 2013Date of Patent: July 26, 2016Assignee: General Electric CompanyInventors: Matthew David Butts, Robert Edgar Colborn, Peter John Bonitatibus, Jr., Andrew Soliz Torres, Brian Christopher Bales, Michael Ernest Marino, Bruce Allan Hay, Amit Mohan Kulkarni
-
Publication number: 20160146795Abstract: A modified porous membrane comprising a polymer coating grafted to a porous membrane is described. A method for analyte detection from a biological sample using an immunoassay is also provided using the modified membrane, wherein the method comprises a) providing a modified porous membrane having the structure of Formula (I), b) incubating the modified porous membrane with a first biomolecule, wherein the first biomolecule binds to the modified porous membrane to form a first biomolecule bound modified porous membrane; and c) adding a biological sample comprising at least an analyte to the first biomolecule bound modified porous membrane for analyte detection by binding the analyte to the first biomolecule bound to the modified porous membrane.Type: ApplicationFiled: November 20, 2014Publication date: May 26, 2016Inventors: Bing Li, Brian Christopher Bales, David Roger Moore, Jason Michael Nichols, Cathryn Ellen Olsen, William Christopher Alberts, Frank John Mondello
-
Publication number: 20160146802Abstract: A device comprising a modified porous membrane is provided. The modified porous membrane comprises a polymer coating grafted to a porous membrane. The device is used for analyte detection from a biological sample using an immunoassay. The device comprises a sample application zone at one end of the device for applying a biological sample comprising a target analyte; and a detection zone present at another end of the device, downstream of the sample application zone for detecting the target analyte, wherein the detection zone comprises one or more first biomolecules immobilized on a modified porous membrane having a structure of Formula (I).Type: ApplicationFiled: November 20, 2014Publication date: May 26, 2016Inventors: Bing Li, Brian Christopher Bales, David Roger Moore, Jason Michael Nichols, Cathryn Ellen Olsen, William Christopher Alberts, Frank John Mondello
-
Publication number: 20160038617Abstract: The present application discloses treating water insoluble nanoparticles, particularly nanoparticles of metals and metal compounds which find utility in diagnostic imaging such as MR and X-ray imaging, with an alpha-hydroxyphosphonic acid conjugate with a hydrophilic moiety to render the nanoparticles sufficiently hydrophilic to find utility in diagnostic imaging. Among the modified hydrophilic nanoparticles disclosed are those in which the hydrophilic moieties of the modifying conjugate are ethylene oxide based polymers and copolymers and zwitterions and the nanoparticles are composed of transition metal oxides such as superparamagnetic iron oxide and tantalum oxide. Disclosed are nanoparticles which are sufficiently hydrophilic to form stable aqueous colloidal suspensions. Also disclosed is diagnostic imaging such as MR and X-ray using the modified hydrophilic nanoparticles as contrast agents.Type: ApplicationFiled: October 21, 2015Publication date: February 11, 2016Inventors: Brian Christopher Bales, Bruce Allan Hay, Binil Itty Ipe Kandapallil
-
Patent number: 9251937Abstract: A method of sterilizing a nanoparticle preparation at a high temperature is provided. A plurality of nanoparticles are purified to form the preparation, wherein the nanoparticles comprise at least a core and a shell and the shell comprises one or more ligand species attached to the core. The nanoparticle preparation is made by a purified nanoparticle composition, a carrier fluid and an excess of the one or more ligand species not attached to the core. The ligand species attached to the core and the excess ligand species added after purification are structurally identical. The nanoparticle preparation provided by the present invention may be used as contrast agents in medical imaging techniques such as X-ray and magnetic resonance imaging.Type: GrantFiled: June 29, 2012Date of Patent: February 2, 2016Assignee: General Electric CompanyInventors: Brian Christopher Bales, Brian James Grimmond, Daniel Eugene Meyer, Bruce Allan Hay, Michael Todd Luttrell
-
Patent number: 9205155Abstract: The present application discloses treating water insoluble nanoparticles, particularly nanoparticles of metals and metal compounds which find utility in diagnostic imaging such as MR and X-ray imaging, with an alpha-hydroxyphosphonic acid conjugate with a hydrophilic moiety to render the nanoparticles sufficiently hydrophilic to find utility in diagnostic imaging. Among the modified hydrophilic nanoparticles disclosed are those in which the hydrophilic moieties of the modifying conjugate are ethylene oxide based polymers and copolymers and zwitterions and the nanoparticles are composed of transition metal oxides such as superparamagnetic iron oxide and tantalum oxide. Disclosed are nanoparticles which are sufficiently hydrophilic to form stable aqueous colloidal suspensions. Also disclosed is diagnostic imaging such as MR and X-ray using the modified hydrophilic nanoparticles as contrast agents.Type: GrantFiled: October 30, 2009Date of Patent: December 8, 2015Assignee: General Electric CompanyInventors: Brian Christopher Bales, Bruce Allan Hay, Binil Itty Ipe Kandapallil